<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04009083</url>
  </required_header>
  <id_info>
    <org_study_id>19-00123</org_study_id>
    <nct_id>NCT04009083</nct_id>
  </id_info>
  <brief_title>Axumin PETMRI Imaging Following Focal Cryo-ablation (FCA)</brief_title>
  <official_title>CLINICAL UTILITY OF AXUMIN PET/MRI IMAGING TWO YEARS FOLLOWING FOCAL CRYO-ABLATION (FCA) OF PROSTATE CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective outcomes study assessing quality of life and oncological control at
      pre-defined time points following FOCAL CRYO-ABLATION (FCA). The investigator's standard of
      care is to perform an Magentic Resonance Imaging (MRI) and prostate biopsy two years
      following FCA. The prostate biopsy assesses both the presence of in field and out of field
      disease. The role of Axumin PET/MRI for detecting disease following FCA has not been
      previously examined.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary hypothesis of this study is that 18F-Fluciclovine PET/MRI imaging at two years
      following FCA will improve sensitivity for detection of in field recurrence of significant
      prostate cancer defined as any Gleason pattern 4 disease.

      The secondary hypothesis of this study is that 18F-Fluciclovine PET/MRI imaging at two years
      following FCA will improve sensitivity for detection of out of field recurrence of
      significant prostate cancer .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of sensitivity following PET imaging with 18-F fluciclovine (Axumin)</measure>
    <time_frame>1 Day</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>18F-Fluciclovine PET Scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard of Care MRI</intervention_name>
    <description>Prostate MRI, serum Prostate Specific Antigen (PSA), in field and random systemic prostate biopsies</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fluciclovine PET scan added to MRI</intervention_name>
    <description>18F-Fluciclovine (Axumin) is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment</description>
    <arm_group_label>18F-Fluciclovine PET Scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  FCA at NYU Langone Health performed at least two years prior to study enrollment by
             Drs. Lepor or Wysock.

          -  No prostate cancer specific treatment following FCA

          -  Consented to undergo reflex MRI and prostate biopsy two years following FCA.

        Exclusion Criteria:

          -  Any contraindication to prostate biopsy

          -  Prior allergic reaction to 18F-Fluciclovine

          -  Patient refuses MRI and prostate biopsy two years following FCA.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Lepor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rozalba Gogaj</last_name>
    <phone>(646)-825-6356</phone>
    <email>Rozalba.Gogaj@nyulangone.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rozalba Gogaj</last_name>
      <phone>646-825-6356</phone>
      <email>Rozalba.Gogaj@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Herbert Lepor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 2, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>18F-Fluciclovine PET imaging</keyword>
  <keyword>Focal Cryo Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

